Targeting Allergic Disease at its source
Cellergy Pharma is developing a first-in-class CAR T cell immunotherapy for treating severe allergic diseases.
Revolutionizing the treatment of severe allergic diseases
Immune-mediated Diseases
Cellergy Pharma is at the forefront of moving CAR T cells beyond the treatment of cancer, to the treatment of diseases caused by the immune system
IgE-mediated Allergic Diseases
Cellergy Pharma’s CAR T cells target and eliminate the cells that cause allergic diseases - IgE-producing cells.
Markets
Cellergy Pharma is targeting two large underserved severe allergic disease markets - uncontrollable severe allergic asthma and severe food allergy.